Existing investors Domain Associates, Latterell Venture Partners, Novo, Mitsui Ventures, Royal Bank of Canada and The Vertical Group also participated in the financing.
Tim Harkness, president and CEO of Cell Biosciences, said: “We are very happy to announce this financing in the current economic environment and we believe it represents a strong vote of confidence by our investors in the potential of the technology and team at Cell Biosciences.
“This investment should allow us to fully execute our plan to bring this revolutionary proteomics technology to the broad life sciences market.”